Show simple item record

dc.contributor.authorAkhtar, Shabana
dc.contributor.authorNajafzadeh, Mojgan
dc.contributor.authorIsreb, Mohammad
dc.contributor.authorNewton, L.
dc.contributor.authorGopalan, Rajendran C.
dc.contributor.authorAnderson, Diana
dc.date.accessioned2020-06-15T17:08:08Z
dc.date.accessioned2020-07-09T08:29:35Z
dc.date.available2020-06-15T17:08:08Z
dc.date.available2020-07-09T08:29:35Z
dc.date.issued2020-07
dc.identifier.citationAkhtar S, Najafzadeh M, Isreb M et al (2020) An in vitro investigation into the protective and genotoxic effects of myricetin bulk and nano forms in lymphocytes of MGUS patients and healthy individuals. Toxicology Letters. 327: 33-40.en_US
dc.identifier.urihttp://hdl.handle.net/10454/17914
dc.descriptionYesen_US
dc.description.abstractThe present study investigated the genoprotective and genotoxic effects of myricetin bulk (10 μM) and nano forms (20 μM) in the lymphocytes from pre-cancerous, monoclonal gammopathy of unknown significance (MGUS) patients and healthy individuals using the Comet and micronucleus assays. The study also evaluated the effect of myricetin on P53 expression levels, using the Western blot technique. Results showed that throughout the in-vitro treatment, lymphocytes from the patients group had higher levels of baseline DNA damage compared to the healthy group. Myricetin in both forms induced significant DNA damage, only at higher concentrations (>40 μM). The micronucleus assay showed a significant reduction (P < 0.01) in the frequency of micronuclei in mono-nucleated cells in the patient group treated with the nano form of myricetin at the non-toxic dose of 20 μM. There was a significant increase in both gene and protein P53 levels in lymphocytes isolated from healthy individuals and pre-cancerous patients. These results suggested a protective effect of myricetin and indicated its nutritional supplement potential for protection against cancer development among patients suffering from MGUS.en_US
dc.description.sponsorshipThis study was kindly funded by Mr Nasir Qayyum, Bradford, UK.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1016/j.toxlet.2020.03.012en_US
dc.rights© 2020 Elsevier B.V. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.
dc.subjectMyricetinen_US
dc.subjectBulk and nano formsen_US
dc.subjectLymphocytesen_US
dc.subjectPre-cancerous patientsen_US
dc.subjectHealthy individualsen_US
dc.subjectGenoprotectiveen_US
dc.subjectP53en_US
dc.subjectATMen_US
dc.subjectComet and micronucleus assaysen_US
dc.titleAn in vitro investigation into the protective and genotoxic effects of myricetin bulk and nano forms in lymphocytes of MGUS patients and healthy individualsen_US
dc.status.refereedYesen_US
dc.date.Accepted2020-03-17
dc.date.application2020-03-24
dc.typeArticleen_US
dc.date.EndofEmbargo2021-03-25
dc.type.versionAccepted Manuscripten_US
dc.description.publicnotesThe full-text of this article will be released for public view at the end of the publisher embargo on 25 Mar 2021.
dc.date.updated2020-06-15T16:08:09Z


Item file(s)

Thumbnail
Name:
Gopalan_et_al_Toxicology_Lette ...
Embargo:
2021-03-25
Size:
387.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record